385 results about "Nutraceutical" patented technology

The present invention relates to concentrates obtained from extraction from Cannabis, preferably cannabinoid and/or terpene concentrates, and formulation of the concentrates, particularly for use for direct vaporization, infusion into edible matrices, in electronic inhalation devices, and as nutraceuticals.

The present invention relates to packaging in the form of a pouch, which may contain active substances, such as food products, pharmaceutical agents, nutraceuticals and cosmetic agents, or the like. More specifically, in some embodiments, the present invention provides a pouch, which includes at least one porous substrate encompassing a closed volume and at least one water-soluble film at least partially embedded in the at least one porous substrate. The pouch may contain an active substance within the closed volume, as well as an active substance in the water-soluble film. The present invention also relates to methods of making and using the pouches.

A method for producing a chewing gum with a controlled release active agent, as well as the chewing gum so produced, is obtained by physically modifying the release properties of the active agent, such as a nutraceutical or nutritional supplement, by coating and drying. The active agent is coated by encapsulation, partially coated by agglomeration, entrapped by absorption, or treated by multiple steps of encapsulation, agglomeration, and absorption. The coated active agent is preferably then co-dried and particle sized to produce a release-modified active agent for use in chewing gum. The active agent may also be used in a coating on a chewing gum product, as part of a rolling compound applied to the chewing gum product, or as a part of the liquid in a liquid-center chewing gum product.

Co-crystals comprising at least one nutraceutical compound and at least one co-crystal former with or without impurities. These co-crystals may be included in compositions (optionally also including other components such as pharmaceutically acceptable excipients, other nutritional supplements, etc.) having utility as pharmaceuticals, nutraceuticals, nutritional supplements, and foodstuffs.

The present invention relates to packaging in the form of a pouch, which may contain active substances, such as food products, pharmaceutical agents, nutraceuticals and cosmetic agents, or the like. More specifically, in some embodiments, the present invention provides a pouch, which includes at least one porous substrate encompassing a closed volume and at least one water-soluble film at least partially covering the at least one porous substrate. The pouch may contain an active substance within the closed volume, as well as an active substance in the water-soluble film. The present invention also relates to methods of making and using the pouches.

The present invention relates to methods and systems for providing an animal with a nutraceutical program that is specifically tailored to address the deficiencies and/or needs of the particular animal. Blood is drawn from the animal and analyzed at a lab to obtain blood test results. The blood test results are scored to obtain at least one blood test score for at least one corresponding blood parameter. If the at least one blood test score falls within a normal range but outside of an optimal range, one or more nutraceuticals needed to bring the animal within the optimal range for the at least one corresponding blood parameter are identified. A prescribed dosage amount is then calculated for at least one of the one or more identified nutraceuticals for the animal. The calculation of the prescribed dosage amount is based on at least the blood test score for the corresponding blood parameter and a deviation of the blood test score from the optimal range.

The present disclosure describes a delivery device for administration of nutraceuticals or pharmaceuticals, which device contains a soft gel shell comprising a gelatin-based water soluble film forming polymer, an acid insoluble polymer, and at least one reducing sugar and water, including processes, gel mixtures used for device production, and coatings containing such gel mixtures.

The present invention provides an oral delivery system for creatine. The creatine delivery system may additionally contain other bioactive ingredients such as nutraceuticals, botanicals, and vitamins. The delivery system comprises an ingestible matrix within which a creatine formulation and optionally one or more bioactives are substantially uniformly and completely dispersed and in which degradation of the creatine and other bioactives is minimised or eliminated. The invention also provides methods of preparing and using the delivery system.

A delivery vehicle for bioactive agents and live probiotic microbes to aquatic animals protects the bioactive compounds and microbes from digestion and destruction in the animal stomach. It provides for controlled release of bioactive agents and live probiotic microbes to aquatic animals in the form of dry or wet beadlets with essential nutrients and attractants bound with soluble starch and cross-linked alginate. The bioactive agents and live probiotic microbes can be bound with emulsified high-amylose starch and embedded in the beadlets in the form of microparticles.

The present invention is directed to soft gel compositions, methods of delivery and packaged nutraceuticals of the soft gel compositions that include at least one polymethoxylated flavone and, optionally, at least one tocotrienol. Optional active ingredients include a phytosterol, DHA, EPA, coenzyme Q-10 or an analog thereof and mixtures thereof.

A medicinal composition for treating pain resulting from an inflammatory response comprises at least one pain relieving and anti-inflammatory pharmaceutical and at least one nutraceutical in a pharmaceutically acceptable base. The pharmaceutical is preferably acetaminophen or a non-steroidal anti-inflammatory drug (NSAID). The nutraceutical is preferably an immune booster, an anti-oxidant, a liver protectant, or a joint relief agent. Methods of using these compositions to treat pain caused by inflammation are also disclosed.

The present invention relates to a media mill system and a method using the same to produce fine and ultra-fine particles useful in diagnostic agents, pharmaceuticals, agrochemicals, nutraceuticals and the like.

A method of processing stillage from fermentation derived alcohol is disclosed, including dry-grind ethanol production from corn, by fermentation with filamentous fungi. This produces high-value fungal biomass that can be recovered by screening, is easily dewatered and used as an animal feed, human food or as a source of nutraceuticals. The methodology uses an airlift reactor to enhance the morphology of the fungi for easy harvesting and separation of water for recycling and reuse and to recover added enzymes and mineral acid with the water. The process also separates oil from the stillage. The fungal processing removes organic substances from the water that are otherwise inhibitory to the reuse prospects for the water, i.e. suspended and dissolved organic matter, including glycerol, lactic and acetic acids. The process also separates oil from the stillage by enmeshing the oil in the fungal biomass and can produce more oil through cultivation of oleaginous fungi. This approach generates revenue from low value thin stillage, while substantially reducing stillage processing costs, mainly by averting the need for evaporation of the thin stillage.

The invention relates to methods for preparing individualized dosage forms of medicines, vitamins, mineral supplements and nutraceuticals in capsule or liquid form. The invention also relates to a system for preparing individualized dosage forms in which a processor is configured to identify a medicament formulation for an individual patient's dosaging needs and communicates this formulation information to a dispensing station where a capsule or a formulation of pellets of small diameter size for reconstitution into a liquid or semi-solid is formed that is specific to the individual's dosaging needs.

The present invention provides protein (or peptide)-polysaccharide (or oligosaccharide) conjugates (PPC) as nanocapsular vehicles for nanoencapsulation of biologically active compounds, particularly nutraceuticals. The PPCs efficiently protect both hydrophobic (i.e., water insoluble) and hydrophilic (i.e., water soluble) nutraceuticals, to provide a composition which, when added to a beverage, disperses so as to provide a clear or transparent solution. In some embodiments, the PPCs are Maillard reaction based PPCs. Advantageously, the conjugates of the present invention protect the nutraceuticals from degradation, both during shelf life and upon gastric digestion.

Activated fatty acids, nutraceutical compositions including activated fatty acids, methods for using activated fatty acids to treat a variety of diseases, and methods for preparing activated fatty acids are provided herein.

A Phytoceutical composition for the prevention and treatment of Parkinson's disease is provided. A specific combination of extracts of plants and nutraceuticals is based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization. Such combination has synergistic effects, with minimal side effects.

A highly refined cellulose material is a composition of matter is used as an ingredient in the preparation of a neutraceutical in liquid, solid, or tablet form. These compositions may provide an expectation of a health benefit selected from the group consisting of Antioxidation; Cancer prevention; Arterial health improvement; Cholesterol lowering; Reduced blood pressure; Skin and wrinkle treatment; and Prolonging and/or delaying release of a nutrient into a bloodstream.

This invention relates to methods and systems for generating a safe and effective oral smallpox vaccine for humans using a genetically defective strain of vaccinia virus to confer immunity following oral delivery of the vaccine. This invention is one that expands on current use of vaccinia virus propagation developed for gene therapy applications, and pharmaceuticals and nutraceuticals packaging and formualtion technologies. The vaccine invention can be delivered as a live virus with the ability to express viral proteins but unable to achieve complete, lytic virus replication, or it may be derived from such a virus, contain additional immunogens, or be delivered as viral antigens. Furthermore, the invention establishes innovative methods for formulation and packaging and for preclinical testing of the vaccine invention for safety, efficacy and potency with the use of human intestinal and other test cells and diagnostic test systems and kits.